Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Isolagen initiates Phase III trial for acne scars therapy
These trials will evaluate the safety and efficacy of Isolagen therapy in patients with moderate to severe acne scarring on both sides of the face. All patients in
These trials will evaluate the safety and efficacy of Isolagen therapy in patients with moderate to severe acne scarring on both sides of the face. All patients in
The prospective, randomized, double-blinded international study was done on an outpatient basis with the primary endpoint being a change in baseline peak walking time, comparing those given rifalazil
The results from comparative trial were presented at the Annual Scientific Sessions of the American Heart Association. All 8,888 patients enrolled in the trial had a prior heart
Wright Medical expects hip resurfacing with the Conserve Plus system is to be an effective option for young, active patients suffering from chronic hip pain. In suitable patients,
Presented data is for patients who completed 24 weeks of treatment in an ongoing 48-week, US trial. A protocol-mandated, external expert panel assessed clinical photographs of 37 onychomycosis
The Phase I study is comparing the bioavailability, pharmacokinetics, pharmacodynamics and safety of picoplatin administered orally with picoplatin administered intravenously in patients with advanced solid tumor malignancies. Bioavailability
Under the terms of the agreement, TriLink is providing Applied Biosystems with custom dye-labeled oligonucleotides, or chemically synthesized nucleotides, which are used as part of the DNA sequencing
This is the third consecutive year in which PharmAthene has received appropriations funding for Valortim, a fully human monoclonal antibody generated by Medarex’s UltiMAb technology that is being
PsychoGenics and Cephalon expect to jointly identify drug candidates suitable for clinical development. If Cephalon develops clinical candidates, PsychoGenics will receive milestone payments as well as royalties. If
The FDA said that the abbreviated new drug application (ANDA) was not approvable because the application does not adequately address the potential for immunogenicity of the drug product